GlaxoSmithKline Pharmaceuticals Limited (500660) Fair Value & Analysis
Healthcare · IN · Market cap ₹248B
Fair value as of: Aug 13, 2026
From 23 valuation models · updated yesterday
Fair value updated Aug 13, 2026, revised from ₹1,471 to ₹1,452 (−1.3%) since Aug 2, 2026. Share price +8.2% over the past month.
A strong business, but screening 46% overvalued on our models.
What matters now
- A high-quality business (quality 81/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (₹2,482). The favourable scenario is already priced in.
- A fairly wide model range (₹1,032 to ₹2,482) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹1,138 – ₹3,370 · fair‑value band ₹1,032 – ₹2,482 · the ₹2,689 price screens above the ₹1,452 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
GlaxoSmithKline Pharmaceuticals Limited (500660) currently trades at ₹2,689, while our model-based Fair Value estimate is ₹1,452, implying the stock looks roughly 46.0% overvalued today. The Quality Score stands at 81/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Our scenario range runs from ₹1,032 (bear case) to ₹2,482 (bull case); at ₹2,689, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 6% below its 52-week high and 29% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at -46%, 500660 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (₹1,942) versus Asset-Based (₹163.19). Highest evidence: Growth DCF (80).
Notify me when 500660 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 79 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, manufactures, and distributes pharmaceutical products and vaccines worldwide. It offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, digestive conditions, and other diseases; and vaccines for various therapeutic areas, primarily cancer.
Full company description
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, manufactures, and distributes pharmaceutical products and vaccines worldwide. It offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, digestive conditions, and other diseases; and vaccines for various therapeutic areas, primarily cancer. The company also provides medicinal substances, such as antibiotics, endocrine products, and basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, and its salts and esters; glycosides and vegetable alkaloids; and chemically pure sugar. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is headquartered in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹38.1B in FY2025 versus ₹32.8B in FY2021, a compound +3.8%/yr. Reported net income was ₹10.4B in FY2025, compounding −11.6%/yr from FY2021.
500660 screens 46% overvalued. Compare with Torrent Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceuticals median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Torrent Pharmaceuticals Limited 500420 | ₹4,876 | ₹4,360 | -11% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| Oscotec Inc 039200 | 38,800 KRW | 33,210 KRW | -14% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| Kolon Life Science Inc 102940 | 17,460 KRW | 37,129 KRW | +113% |
| Huons Global Co 084110 | 25,100 KRW | 58,482 KRW | +133% |
| BINEX Co 053030 | 7,300 KRW | 1,844 KRW | -75% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 15,520 KRW | 4,741 KRW | -69% |
| Kyung Dong Pharmaceutical Co 011040 | 5,180 KRW | 6,165 KRW | +19% |
Compare GlaxoSmithKline Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GlaxoSmithKline Pharmaceuticals Limited (500660) overvalued or undervalued?
What is the fair value of 500660?
What is the quality score of 500660?
What is the net profit margin of 500660?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GlaxoSmithKline Pharmaceuticals Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.